Induction of labour in postdates pregnant women.
OBJECTIVE
To differentiate the effect of gestation on the mode of delivery by analysing the difference in the mode of induction, length of labour and the difference in parity or Bishop score and their effect on the mode of delivery of postdates women.


METHODS
A cross-sectional observational study.


METHODS
PAEC General Hospital, Islamabad, from July 2006 to July 2008.


METHODS
Patients were induced at 41 weeks (Group B) and > 40 weeks (Group A) of gestation. Tab misoprostol and PGE2 tablets were administered according to amniotic fluid index (AFI) and parity. Study variables included duration of gestation, mode of induction, length of labour, difference in parity and Bishop score assessed before induction in each group. The outcome was assessed by applying Chi-square test by comparing mode of delivery with the study variables in both groups.


RESULTS
A total of 78 patients were inducted in the study. They were divided in group B (n = 39) induced 41 weeks and group A (n = 39) induced at 40 weeks. Eighty four percent (n = 35) patients in group B delivered vaginally as compared to 71% (n = 28) in the 40 weeks group (p < 0.0001). The higher number of vaginal deliveries in 41 weeks group was independent of association between the induction agent, parity and mode of delivery.


CONCLUSIONS
The mean length of gestation was the single most important factor among the studied variables in predicting a vaginal delivery.
Department of Obstetrics and Gynaecology, PAEC General Hospital, Islamabad, Pakistan. crooji@yahoo.com
Ambreen Naveed
AN
Haq
Saadat
S
Ahsan
Zaiba
Z
Sher
D000284:Administration, Oral; D000328:Adult; D000653:Amniotic Fluid; D020070:Cervical Ripening / Q000502:physiology; D003430:Cross-Sectional Studies; D036861:Delivery, Obstetric / Q000379:methods* / Q000706:statistics & numerical data; D015232:Dinoprostone / Q000008:administration & dosage*; D005260:Female; D005865:Gestational Age; D006801:Humans; D007751:Labor, Induced; D016595:Misoprostol / Q000008:administration & dosage*; D010120:Oxytocics / Q000008:administration & dosage*; D010298:Parity; D011247:Pregnancy; D011248:Pregnancy Complications; D011256:Pregnancy Outcome; D011273:Pregnancy, Prolonged / Q000188:drug therapy* / Q000453:epidemiology; D055815:Young Adult
D010120:Oxytocics; D016595:Misoprostol; D015232:Dinoprostone